The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is the most impactful, largest, and longest continually monitored Alzheimer's disease study.

The National Institute on Aging (NIA) launched ADNI in 2004, to develop and validate biomarkers to improve the speed and success rate of clinical trials for Alzheimer’s disease (AD).

The FNIH convened for nearly two decades a public-private partnership that supported ADNI. This was a revolutionary concept at the time, and the first time that researchers from different institutions, private and public organizations worked together with a common purpose and objective. ADNI was, in fact, the first large collaboration among government organizations, pharmaceutical organizations, and non-profit organizations. This innovative partnership model for collaborative research enabled an unprecedented level of open data and samples sharing, transforming the global clinical trial landscape for patients.

ADNI’s legacy lives on through ongoing collaborations between the public and private sectors, such as the Biomarkers Consortium and the Accelerating Medicines Partnership (AMP®) – Alzheimer’s Disease. Numerous projects have been generated due to the lessons learned from ADNI, and the neuroscience field continues to move forward.

Impact
  • 6

    NIH institutes

  • 157

    Private Partners

  • 3,700+

    Scientific Publications

  • 23K+

    Brain Imaging Scans

  • 1M+

    Biosamples

Closed Projects

ADNI History (ADNI 1, ADNI 2, ADNI 3)

ADNI began in 2004, when the National Institute on Aging (NIA) recognized the critical need to develop and validate biomarkers to improve the speed and success rate of clinical trials for Alzheimer’s disease (AD). Understanding that such a colossal undertaking required significant investment, intellectual contribution, and a variety of skill sets, ADNI was designed, structured, and operated as a public-private partnership, managed by the FNIH.
Under the leadership of Dr. Michael W. Weiner, ADNI1 was funded as a private-public partnership with $26 million contributed by 20 companies and two foundations through the FNIH and $42 million from the NIA. The initial five-year study (ADNI-1) was extended by two years in 2009 by a Grand Opportunities grant (ADNI-GO), and in 2011 and 2016 by further competitive renewals of the ADNI-1 grant (ADNI-2, and ADNI-3, respectively).

Over nearly two decades, ADNI underwent multiple peer-reviewed renewals and federal funding (including ADNI1, ADNI-GO, ADNI2, ADNI3, and ADNI4, with the FNIH managing 160 partners and individual donors who contributed a staggering $210 million to the cause with, $145 million from the public sector and $65 million from the private sector.
After relying on a public-private partnership for funding and advancing ADNI, the NIA funded the current phase of ADNI (ADNI 4) entirely with federal funds, which successfully ended the FNIH’s role in managing the Public-Private Partnership.

ADNI4, continues the program’s legacy of developing tools and methodologies to advance treatment trials for AD. And the Alzheimer’s Association has taken over coordination of the PPSB, ensuring that the public and private sectors will continue to interact and collaborate.

Public Partner Scientific Board (PPSB)

The Public Partner Scientific Board (PPSB) was created and managed by the FNIH as an independent advisory board composed of members from the private sector, biotech, diagnostics, and non-profits.
The PPSB has been the key of ADNI’s success. It provided financial support, but members of the PPSB also shared their insights, advice, and suggestions, all of which proved vital in advancing ADNI’s mission.

The PPSB managed various Workgroups (Clinical Endpoints, PET Endpoints, MRI Core Assessment and Privacy, Fluid Biomarkers, Genetics, and Systems.) which were instrumental in evaluating emerging technologies and making decisions about ADNI’s structure.

In addition, the PPSB also funded and ran add-on projects that were not part of the original ADNI project. Endpoints now routinely used in clinical trials (FDG PET, amyloid PET, AD Assessment Scale – Cognitive Subscale (ADAS-Cog)) are the result of refinement, improvement, and guidance from PPSB workgroups.

ADNI’s legacy lives on through ongoing collaborations between the public and private sectors, such as the Biomarkers Consortium and the Accelerating Medicines Partnership (AMP®) – Alzheimer’s Disease. Numerous projects have been generated due to the lessons learned from ADNI, and the neuroscience field continues to move forward.

ADNI data has enabled to better understand disease progression and enhance patient selection and trial design.

-Samantha Budd Haeberlein, Ph.D., Senior Vice President, Head Neurodegeneration Development Unit, Biogen
nord logo

Partners

Private Sector
  • Abbott Laboratories
  • AbbVie
  • Accelerate Cure/Treatments for All Dementias (ACT-AD)
  • Alzheimer's Association
  • Alzheimer’s Drug Discovery Foundation
  • Alector
  • Araclon Biotech
  • AstraZeneca
  • Bayer Healthcare
  • Biogen
  • Bristol-Myers Squibb
  • C2N Diagnostics
  • Cerespir Incorporated
  • Clario
  • Cogstate
  • Cure Alzheimer’s Fund
  • Denali Therapeutics
  • DiamiR Biosciences
  • Eisai
  • Elan Pharmaceuticals
  • Eli Lilly and Company
  • EUROIMMUN US
  • FUJIFILM Toyama Chemical Co.
  • Fujirebio
  • GE Healthcare
  • Grifols
  • H. Lundbeck
  • Institute for the Study of Aging
  • Invicro
  • IXICO
  • Janssen Research & Development
  • Life Molecular Imaging
  • Lumos Labs
  • MagQu Co.
  • MEDPACE
  • Merck
  • Meso Scale Diagnostics
  • NeuroRx
  • Neurotrack Technologies
  • Novartis
  • OPKO Health
  • PeopleBio
  • Pfizer
  • ProMIS Neurosciences
  • Roche
  • Genentech
  • Saladax Biomedical
  • Servier
  • Takeda
Public Sector
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Drug Abuse
  • National Institutes of Health Office of the Director
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke
  • Canadian Institutes of Health Research (CIHR IRSC)
Academia
  • Michael W. Weiner, M.D., Lead Principal Investigator
  • 10 national principal investigators leading scientific cores
  • 1 academic clinical research center
  • 59 participant enrollment sites
CONTACT

Diseases

Partner With Us